Genmab A/S
GMAB
Cena:
$ 26.87
-0.18 (-0.67%)
Valuace
70
Růst
0
Zdraví
78
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
GRANT OF RESTRICTED STOCK UNITS AND WARRANTS TO EMPLOYEES IN GENMAB
29-01-2026
COMPANY ANNOUNCEMENT COPENHAGEN, DENMARK; JANUARY 29, 2026 – GENMAB A/S (NASDAQ: GMAB) ANNOUNCED T...
Více zde
GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR 2025
21-01-2026
COMPANY ANNOUNCEMENT NET SALES OF DARZALEX ® IN 2025 TOTALED USD 14,351 MILLION GENMAB RECEIVES ROY...
Více zde
GENMAB ANNOUNCES TOPLINE RESULTS FOR EPCORITAMAB (DUOBODY® CD3XCD20) FROM PHASE 3 EPCORE® DLBCL-1 TRIAL IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
16-01-2026
COPENHAGEN, DENMARK--(BUSINESS WIRE)--GENMAB A/S (NASDAQ: GMAB) TODAY ANNOUNCED TOPLINE RESULTS FROM...
Více zde
GENMAB ANNOUNCES TOPLINE RESULTS FOR EPCORITAMAB (DUOBODY® CD3XCD20) FROM PHASE 3 EPCORE® DLBCL-1 TRIAL IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
16-01-2026
COMPANY ANNOUNCEMENT BASED ON THE TOPLINE RESULTS FROM THE EPCORE ® DLBCL-1 TRIAL, GENMAB WILL ENGA...
Více zde
GENMAB PARTNERS WITH ANTHROPIC TO ACCELERATE RESEARCH AND DEVELOPMENT THROUGH AGENTIC ARTIFICIAL INTELLIGENCE
07-01-2026
COPENHAGEN, DENMARK--(BUSINESS WIRE)-- #AI--GENMAB HAS PARTNERED WITH ANTHROPIC TO ADVANCE ITS RESEA...
Více zde
GENMAB TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
05-01-2026
MEDIA RELEASE COPENHAGEN, DENMARK; JANUARY 5, 2026 GENMAB A/S (NASDAQ: GMAB) ANNOUNCED TODAY THA...
Více zde
GENMAB PORTFOLIO PRIORITIZATION UPDATE
29-12-2025
COPENHAGEN, DENMARK--(BUSINESS WIRE)--GENMAB A/S (NASDAQ: GMAB) ANNOUNCED TODAY THAT IT WILL DISCONT...
Více zde
GENMAB PORTFOLIO PRIORITIZATION UPDATE
29-12-2025
COMPANY ANNOUNCEMENT GENMAB TO DISCONTINUE CLINICAL DEVELOPMENT OF ACASUNLIMAB FOLLOWING A PORTFOLIO...
Více zde
GENMAB ANNOUNCES COMPLETION OF TENDER OFFER FOR OUTSTANDING COMMON SHARES OF MERUS N.V. AND COMMENCEMENT OF SUBSEQUENT OFFERING PERIOD
12-12-2025
COPENHAGEN, DENMARK--(BUSINESS WIRE)--GENMAB A/S (NASDAQ: GMAB) (“GENMAB”) ANNOUNCED TODAY THAT ...
Více zde
GENMAB ANNOUNCES COMPLETION OF TENDER OFFER FOR OUTSTANDING COMMON SHARES OF MERUS N.V. AND COMMENCEMENT OF SUBSEQUENT OFFERING PERIOD
12-12-2025
COMPANY ANNOUNCEMENT TRANSACTION ADDS PETOSEMTAMAB, A LATE-STAGE ASSET WITH TWO BREAKTHROUGH THERAPY...
Více zde
GENMAB TO HOLD 2025 R&D UPDATE AND ASH DATA REVIEW MEETING
11-12-2025
MEDIA RELEASE EVENT TO BE HELD VIRTUALLY VIA LIVE WEBCAST AND ARCHIVED ON WWW.GENMAB.COM COPENHAGEN,...
Více zde
GENMAB ANNOUNCES NEW DATA FROM PHASE 1B/2 EPCORE® CLL-1 HIGHLIGHTING POTENTIAL OF EPCORITAMAB AS MONOTHERAPY AND IN COMBINATION FOR PATIENTS WITH RICHTER TRANSFORMATION (RT)
08-12-2025
COPENHAGEN, DENMARK--(BUSINESS WIRE)--GENMAB A/S (NASDAQ: GMAB) TODAY ANNOUNCED NEW AND UPDATED DATA...
Více zde
GENMAB PRESENTS PIVOTAL PHASE 3 DATA FROM EPCORE® FL-1 TRIAL DEMONSTRATING CLINICAL BENEFIT OF EPKINLY® (EPCORITAMAB-BYSP) IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE (R2) IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
07-12-2025
COPENHAGEN, DENMARK--(BUSINESS WIRE)--GENMAB A/S (NASDAQ: GMAB) TODAY ANNOUNCED PRIMARY DATA FROM TH...
Více zde
GENMAB ANNOUNCES DATA FROM MULTIPLE CLINICAL TRIALS SHOWING TREATMENT WITH FIXED-DURATION EPCORITAMAB LED TO REMISSIONS IN FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND FOLLICULAR LYMPHOMA (FL)
06-12-2025
COPENHAGEN, DENMARK--(BUSINESS WIRE)--GENMAB A/S (NASDAQ: GMAB) TODAY ANNOUNCED UPDATED RESULTS FROM...
Více zde
GENMAB ANNOUNCES CLOSING OF PRIVATE OFFERING OF SENIOR SECURED NOTES AND SENIOR UNSECURED NOTES
03-12-2025
MEDIA RELEASE COPENHAGEN, DENMARK; DECEMBER 3, 2025 GENMAB A/S (NASDAQ: GMAB) (“GENMAB”) ANNOUNC...
Více zde
TRANSACTIONS WITH SHARES AND LINKED SECURITIES IN GENMAB A/S MADE BY MANAGERIAL EMPLOYEES AND THEIR CLOSELY ASSOCIATED PERSONS
01-12-2025
COMPANY ANNOUNCEMENT COPENHAGEN, DENMARK; DECEMBER 1, 2025 – GENMAB A/S (NASDAQ: GMAB) – IN ACCO...
Více zde
GENMAB TO PARTICIPATE IN A FIRESIDE CHAT AT THE CITI GLOBAL HEALTHCARE CONFERENCE IN MIAMI
24-11-2025
MEDIA RELEASE COPENHAGEN, DENMARK; NOVEMBER 24, 2025 GENMAB A/S (NASDAQ: GMAB ) ANNOUNCED TODAY THAT...
Více zde
GRANT OF RESTRICTED STOCK UNITS AND WARRANTS TO EMPLOYEES IN GENMAB
20-11-2025
COMPANY ANNOUNCEMENT COPENHAGEN, DENMARK; NOVEMBER 20, 2025 – GENMAB A/S (NASDAQ: GMAB) ANNOUNCED ...
Více zde
TRANSACTIONS WITH SHARES AND LINKED SECURITIES IN GENMAB A/S MADE BY MANAGERIAL EMPLOYEES AND THEIR CLOSELY ASSOCIATED PERSONS
19-11-2025
COMPANY ANNOUNCEMENT COPENHAGEN, DENMARK; NOVEMBER 19, 2025 – GENMAB A/S (NASDAQ: GMAB) - IN ACCOR...
Více zde
GENMAB ANNOUNCES PRICING OF PRIVATE OFFERING OF SENIOR SECURED NOTES AND SENIOR UNSECURED NOTES AND COMPLETION OF SYNDICATION OF NEW SENIOR SECURED TERM LOAN FACILITY
18-11-2025
MEDIA RELEASE COPENHAGEN, DENMARK; NOVEMBER 18, 2025 GENMAB A/S (NASDAQ: GMAB) (“GENMAB”) ANNOUN...
Více zde
CAPITAL INCREASE IN GENMAB AS A RESULT OF EMPLOYEE WARRANT EXERCISE
18-11-2025
COMPANY ANNOUNCEMENT COPENHAGEN, DENMARK; NOVEMBER 18, 2025 – GENMAB A/S (NASDAQ: GMAB) WILL INCRE...
Více zde
GENMAB ANNOUNCES EPKINLY® (EPCORITAMAB-BYSP) IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
18-11-2025
COPENHAGEN, DENMARK--(BUSINESS WIRE)--GENMAB A/S (NASDAQ: GMAB) ANNOUNCED TODAY THAT EPKINLY® (EPCO...
Více zde
GENMAB PROVIDES CERTAIN INFORMATION DISCLOSED IN CONNECTION WITH PROPOSED PRIVATE OFFERING OF SENIOR SECURED NOTES AND SENIOR UNSECURED NOTES
10-11-2025
MEDIA RELEASE COPENHAGEN, DENMARK; NOVEMBER 10, 2025 GENMAB A/S (“GENMAB”) ANNOUNCED ON NOVEMBER...
Více zde
GENMAB ANNOUNCES PROPOSED PRIVATE OFFERING OF SENIOR SECURED NOTES AND SENIOR UNSECURED NOTES AND SYNDICATION OF NEW SENIOR SECURED TERM LOAN FACILITY
10-11-2025
MEDIA RELEASE COPENHAGEN, DENMARK; NOVEMBER 10, 2025 GENMAB A/S (NASDAQ: GMAB) (“GENMAB”) ANNOUN...
Více zde
GENMAB TO PARTICIPATE IN A FIRESIDE CHAT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON
05-11-2025
MEDIA RELEASE COPENHAGEN, DENMARK; NOVEMBER 5, 2025 GENMAB A/S (NASDAQ: GMAB ) ANNOUNCED TODAY THAT ...
Více zde
GENMAB TO SHOWCASE LATEST BLOOD CANCER TREATMENT ADVANCEMENTS AT 2025 AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING
03-11-2025
COPENHAGEN, DENMARK--(BUSINESS WIRE)--GENMAB A/S (NASDAQ: GMAB) TODAY ANNOUNCED THAT MORE THAN 20 AB...
Více zde
MERUS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF MERUS N.V. - MRUS
23-10-2025
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ...
Více zde
GENMAB COMMENCES TENDER OFFER FOR ALL ISSUED AND OUTSTANDING COMMON SHARES OF MERUS N.V.
21-10-2025
MEDIA RELEASE COPENHAGEN, DENMARK; OCTOBER 21, 2025 GENMAB A/S (NASDAQ: G MAB ) (“GENMAB”) ANNOU...
Více zde
GENMAB ANNOUNCES NEW DATA DEMONSTRATING INVESTIGATIONAL RINATABART SESUTECAN (RINA-S®) ACHIEVED ANTI-TUMOR ACTIVITY IN HEAVILY PRETREATED PATIENTS WITH ADVANCED ENDOMETRIAL CANCER
18-10-2025
COPENHAGEN, DENMARK--(BUSINESS WIRE)--GENMAB A/S (NASDAQ: GMAB) ANNOUNCED TODAY UPDATED DATA FROM CO...
Více zde
GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR THIRD QUARTER OF 2025
14-10-2025
COMPANY ANNOUNCEMENT NET SALES OF DARZALEX ® IN THE THIRD QUARTER OF 2025 TOTALED USD 3,672 MILLION...
Více zde
Dokumenty nejsou k dispozici
